APG273 (Zumilokibart + APG333)
Asthma / COPD
PreclinicalIn-progress
Key Facts
About Apogee Therapeutics
Founded in 2022, Apogee Therapeutics aims to reshape the standard of care for inflammatory and immune diseases by developing potentially best-in-class biologics with optimized dosing intervals. Its pipeline includes monotherapies and rational combinations targeting validated pathways like IL-13, OX40L, and TSLP across dermatological, respiratory, and gastroenterological conditions. The company is publicly traded (NASDAQ: APGE) and is advancing multiple programs with key clinical readouts expected in 2026.
View full company profileTherapeutic Areas
Other Asthma / COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| Fluticasone Furoate/Vilanterol (Relvar) | KYORIN Pharmaceutical | Approved |